 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 GLOBE NEWSWIRE -- ALX Oncology Holdings Inc., ALX Oncology Nasdaq: ALXO, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the Company will be presenting early clinical data from ASPEN-02, its ongoing Phase 12 study evaluating evorpacept in combination with azacitidine for the treatment of myelodysplastic syndromes MDS in a poster presentation at the 63rd American Society of Hematology ASH Annual Meeting held December 11-14, 2021 in Atlanta, Georgia. 